FDA Safety Alert: AvKARE, LLC. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750 mg/5 mL Due to Potential Bacillus Cereus Contamination

Drugs.com sent this email to their subscribers on April 3, 2024.


Text-only version of this email

You received this email because you are subscribed to updates from Drugs.com. Change your notification settings or . @% Drugs.com FDA Medwatch Alert March 29, 2024 AVKARE, LLC. ISSUES VOLUNTARY NATIONWIDE RECALL OF ATOVAQUONE ORAL SUSPENSION, USP 750 MG/5 ML DUE TO POTENTIAL BACILLUS CEREUS CONTAMINATION Audience: Consumer, Health Professional, Pharmacy March 29, 2024 –AvKARE, LLC is voluntarily recalling lot # AW0221A of Atovaquone Oral Suspension, USP 750mg/5mL to the Consumer/User level, due to the potential Bacillus cereus contamination in the product found during stability testing at a 3rd party lab. Read More DISCOVER A TREATMENT OPTION If you are affected by HIV Infection, help may be at hand. Learn more Follow Us Follow on Facebook Follow on Twitter Follow on YouTube ---------------------------------------------------------------------------------------------------------------------------------- Notification Settings Contact You received this email because you are subscribed to updates from Drugs.com. Any personal information you provide to us will only be used to notify you of offers, information and activities. We'll hold the information about you securely and will not disclose it except for this purpose, or when required by law. Copyright ©2024 Drugs.com, PO Box 302 739, Auckland NZ 0751. All Rights Reserved.
Show all

The Latest Emails Sent By Drugs.com

More Emails, Deals & Coupons From Drugs.com

Email Offers, Discounts & Promos From Our Top Stores